Delving into the Latest Updates on Giuliani Group SA with Synapse

A phase II multicenter, randomized, double-blind, controlled vs placebo, dose-finding study on the efficacy and safety of GED-0301, in patients with active Crohn?s disease (Ileo-Colitis) - I.G.O.N. 1 STUDY

开始日期2013-03-08

申办/合作机构

Giuliani SpA

EUCTR2011-005678-47-IT / Not yet recruitingN/A

A phase II multi-center, randomized, double-blind, controlled vs placebo, long-term extension study to evaluate the safety and tolerability of 40 mg GED-0301for the maintainance of Crohn’s disease in remission. - IGON 2

开始日期2012-01-19

申办/合作机构

Giuliani SpA

EUCTR2011-003283-78-IT / Not yet recruitingN/A

A PROOF-OF-CONCEPT CLINICAL STUDY, TO ASSESS THE EFFECT OF GED-0507-34-Levo 80 mg Tablets IN INDUCTION OF REMISSION OF ACTIVE ULCERATIVE COLITIS

开始日期2012-01-09

申办/合作机构

Giuliani SpA

100 项与 Giuliani Group SA 相关的临床结果

登录后查看更多信息

0 项与 Giuliani Group SA 相关的专利（医药）

登录后查看更多信息

3

项与 Giuliani Group SA 相关的文献（医药）

2013-08-01·Journal of International Medical Research4区 · 医学

A randomized, double-blind, placebo-controlled multicentre study to evaluate the efficacy and safety of diclofenac 4% spray gel in the treatment of acute uncomplicated ankle sprain

4区 · 医学

ArticleOA

作者: Menke, Georg ; Seigfried, Bernd ; Novellini, Roberto ; Predel, Hans-Georg ; Giannetti, Bruno

Objective A prospective, randomized, double-blind, placebo-controlled, parallel-group multicentre study to evaluate the efficacy and safety of diclofenac 4% spray gel for the treatment of acute, uncomplicated ankle sprain. Methods Outpatients with acute, uncomplicated, one-sided ankle sprain were randomly assigned to receive diclofenac 4% spray gel or placebo (vehicle) three times daily for 14 ± 1 days. The main efficacy endpoint was the intra-individual response to treatment (≥50% decrease in swelling of the injured ankle after a treatment period of ≤10 days). Results The response rate was significantly higher in the diclofenac group ( n = 118) than the placebo group ( n = 114) (91.5% vs. 82.5%). After 3–4 days’ treatment, diclofenac spray significantly reduced swelling, spontaneous pain, pain on active movement and tenderness compared with placebo. Diclofenac spray was well tolerated, with a low overall rate of adverse events. Conclusions Diclofenac 4% spray gel rapidly relieves pain and improves mobility in patients with acute, uncomplicated ankle sprain and is well tolerated. It may be a useful treatment option for other acute soft tissue injuries.

1988-04-01·Journal of Medicinal Chemistry1区 · 医学

Bile acids with a cyclopropyl-containing side chain. 3. Separation, identification, and properties of all four stereoisomers of 3.alpha.,7.beta.-dihydroxy-22,23-methylene-5.beta.-cholan-24-oic acid

1区 · 医学

Article

作者: Barry Porter ; Aldo Roda ; Benedetto Natalini ; Brunella Grigolo ; Renzo Balducci ; Roberto Pellicciari ; Sergio Cecchetti

3 alpha,7 beta-Dihydroxy-22,23-methylene-5 beta-cholan-24-oic acid (CUDCA) (2a), a side-chain cyclopropylog of ursodeoxycholic acid (UDCA) was shown to be a mixture of four stereoisomers (CUDCA A-D). The 22S,23R, and 22R,23S diastereoisomers have been separated, their respective configurations assigned by 13C NMR spectroscopy, and original synthetic schemes for their preparation elaborated. Moreover, theoretical models of the structure of UDCA and CUDCA A-D were built by using molecular computer graphic techniques. It was shown that the four diastereoisomers greatly differ in hydrophilicity, in critical micellar concentration (CMC) in water, and exhibit a different interaction with intestinal bacterial enzymes. It was also shown that CUDCA A-C are not conjugated with glycine or taurine in the liver, while CUDCA D is secreted into bile predominantly as taurine and glycine conjugate.

Cosmetic Technology (Milano, Italy)

HIPE - high internal phase emulsions: oil/water emulsions with high internal phases

作者: Mascolo, Antonio ; Pantini, Giovanni ; Giuliani, Giammaria ; Benedusi, Anne

A review of the use of high internal phase oil-in-water emulsions in cosmetics.

100 项与 Giuliani Group SA 相关的药物交易

登录后查看更多信息

100 项与 Giuliani Group SA 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年12月23日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床1期

1

3

临床2期

其他

3

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

MK-52 ( GR )	皮肤疾病更多	临床2期
GED-0507-34 ( PPARγ )	溃疡性结肠炎更多	临床2期
MK-51 ( GR )	皮肤疾病更多	临床2期
MK-49	疼痛更多	临床1期
Tarenflurbil spraygel(Galen) ( AP-1 x APP x NF-κB )	炎症更多	临床阶段不明